As 2024 closes, it is only right to discuss where we are when it comes to AI and where we will be in the future.

As technology continues to evolve and blend into science in 2025 and beyond, a practical approach to what it can and cannot do must be explored.

Additionally, how overpromising while underdelivering has affected investors' and the industry’s confidence in AI.

Host

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpace

Guests

⁠⁠Mike King⁠⁠⁠, Senior Director of Product and Strategy, IQVIA

⁠⁠⁠⁠Moritz von Stosch⁠⁠⁠⁠ Chief Innovation Officer, DataHow

⁠⁠⁠Nindhana Paranthaman⁠⁠⁠, Executive Medical Director, Clinical Development, Summit Therapeutics

⁠⁠⁠⁠Paul Agapow⁠⁠⁠⁠, Head of Data Science, BioNTech